These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

72 related items for PubMed ID: 21993867

  • 1. Effects of zuclopenthixol on aggressive disruptive behavior in adults with mental retardation--a 2-year follow-up on a withdrawal study.
    Hässler F, Glaser T, Reis O.
    Pharmacopsychiatry; 2011 Nov; 44(7):339-43. PubMed ID: 21993867
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of aggressive behavior problems in boys with intellectual disabilities using zuclopenthixol.
    Hässler F, Dück A, Jung M, Reis O.
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):579-81. PubMed ID: 25514543
    [Abstract] [Full Text] [Related]

  • 4. Zuclopenthixol in adults with intellectual disabilities and aggressive behaviours: discontinuation study.
    Haessler F, Glaser T, Beneke M, Pap AF, Bodenschatz R, Reis O, Zuclopenthixol Disruptive Behaviour Study Group.
    Br J Psychiatry; 2007 May; 190():447-8. PubMed ID: 17470962
    [Abstract] [Full Text] [Related]

  • 5. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study.
    Hovens JE, Dries PJ, Melman CT, Wapenaar RJ, Loonen AJ.
    J Psychopharmacol; 2005 Jan; 19(1):51-7. PubMed ID: 15671129
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Zuclopenthixol and haloperidol/levomepromazine in the treatment of elderly patients with symptoms of aggressiveness and agitation: a double-blind, multi-centre study.
    Fuglum E, Schillinger A, Andersen JB, Belstad BE, Jensen D, Müller F, Müller KJ, Schulstad B, Elgen K.
    Pharmatherapeutica; 1989 Jan; 5(5):285-91. PubMed ID: 2568639
    [Abstract] [Full Text] [Related]

  • 9. Pharmacotherapy of disruptive behavior in mentally retarded subjects: A review of the current literature.
    Hässler F, Reis O.
    Dev Disabil Res Rev; 2010 Jan; 16(3):265-72. PubMed ID: 20981765
    [Abstract] [Full Text] [Related]

  • 10. A double-blind comparison of zuclopenthixol tablets with placebo in the treatment of mentally handicapped in-patients with associated behavioural disorders.
    Singh I, Owino WJ.
    J Intellect Disabil Res; 1992 Dec; 36 ( Pt 6)():541-9. PubMed ID: 1477491
    [Abstract] [Full Text] [Related]

  • 11. Zuclopenthixol treatment of behavioral disturbances in mentally retarded children and adolescents: an open-label study.
    Spivak B, Mozes T, Mester R, Kodelik M, Weizman A.
    J Child Adolesc Psychopharmacol; 2001 Dec; 11(3):279-84. PubMed ID: 11642477
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Open multicentre trial of zuclopenthixol in mania and schizophrenia based on the AMDP scales.
    Bobon D, Troisfontaines B, Kempeneers JL, Xhenseval B, Bourdouxhe S, Mirel J, Gilson H, Toussaint C, von Frenckell R, Pedersen V.
    Acta Psychiatr Belg; 1986 Dec; 86(2):152-76. PubMed ID: 2873713
    [Abstract] [Full Text] [Related]

  • 16. Zuclopenthixol decanoate in the management of behavioural disorders in mentally handicapped patients.
    Izmeth MG, Khan SY, Kumarajeewa DI, Shivanathan S, Veall RM, Wiley YV.
    Pharmatherapeutica; 1988 Dec; 5(4):217-27. PubMed ID: 2902642
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G, Safadi G, Beauclair L.
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.